Wanbury LimitedQ1 FY27 Results & Financial Update
Wanbury Limited: Q1 FY27 standalone results and company financials – revenue ₹165.58 Cr, PAT ₹3.24 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Wanbury price & chart
Market price₹201.85
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Wanbury Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Wanbury Limited reported standalone revenue from operations of Rs. 165.58 crore for the quarter ended June 30, 2026, marking a modest 1.5% year-on-year growth compared to Rs. 163.18 crore in Q1 FY26.
Top-line growth during the quarter was constrained by external logistics disruptions arising from the ongoing crisis in the West Asia region, which delayed a portion of scheduled API export dispatches.
Profitability faced severe pressure due to an unprecedented and sudden surge in key input costs, particularly solvents and other crude oil-linked raw materials stemming from the West Asia geopolitical situation.
Gross profit for the quarter stood at Rs. 86.9 crore, with gross margins contracting to 52.5% from 54.0% in the corresponding previous year quarter and 60.4% in Q4 FY26, as the company was unable to immediately pass on the entirety of input inflation during Q1.
Profit after tax (PAT) for Q1 FY27 declined to Rs. 3.24 crore compared to Rs. 13.49 crore in Q1 FY26, translating to a basic EPS of Rs. 0.93.
During the quarter, the company completed a major debt refinancing arrangement, replacing high-cost borrowings with Rs. 205 crore availed from non-banking financial entities (Axis Finance and Poonawalla Fincorp), bringing down borrowing costs to sub-10% effective July 1, 2026.
The debt refinancing enabled the release of 85,20,330 equity shares previously pledged by promoters, freeing up 40.65% of the company's paid-up equity and 94.51% of the promoter group's holding.
Management noted that the input cost pressures are transitory and expects gross and EBITDA margins, along with finance cost savings, to normalize and recover positively starting from Q2 FY27.
01 · Business model
What does Wanbury do?
Wanbury Limited is an established pharmaceutical company operating across active pharmaceutical ingredients (APIs) and domestic branded formulations, backed by over 37 years of operating history.
The company maintains a dual revenue-stream structure, with APIs contributing the majority of top-line revenue through global exports to over 50 countries, and branded formulations serving the domestic Indian market across acute and chronic therapeutic categories.
Wanbury operates two USFDA-approved manufacturing facilities located at Tanuku in Andhra Pradesh and Patalganga in Maharashtra, boasting a cumulative installed reactor capacity supported by dedicated and multi-purpose blocks.
The company's core API portfolio focuses on chronic and high-demand segments including Metformin, Sertraline, Tramadol, Paroxetine, Mefenamic Acid, and Diphenhydramine, alongside newer specialized additions such as anaesthetics.
02 · Historical context
What shaped the business before this quarter
Incorporated as Pearl Organics Pvt. Ltd. in 1990, the company established its first API manufacturing plant in 1992 and subsequently acquired Wander Limited and Brij Chemicals in 1995 before renaming itself Wanbury Limited in 2004.
Over the preceding three years leading up to FY26, Wanbury executed a successful financial and operational turnaround, reducing peak debt obligations by roughly 75% through strategic asset sales, capital infusions, and lender settlements.
The company previously expanded key API capacities through de-bottlenecking—growing Metformin capacity by 25% and Sertraline by 20% over a three-year window—while achieving financial break-even in its formulations business in FY26.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Q1 FY27 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹165.58 Cr | ₹163.18 Cr | ₹164.58 Cr |
| Total income | ₹165.94 Cr | ₹163.53 Cr | ₹164.79 Cr |
| Profit before tax | ₹4.59 Cr | ₹13.61 Cr | ₹15.17 Cr |
| Profit after tax | ₹3.24 Cr | ₹13.49 Cr | ₹21.70 Cr |
| EPS | ₹0.93 | ₹4.12 | ₹7.33 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue growth of 1.5% YoY to Rs. 165.58 crore was held back by logistics disruptions in West Asia that delayed several export dispatches during the quarter.
Top-line expansion is expected to be supported by the commercial scale-up of recently launched API products and a pipeline of new commercial molecule introductions.
What drove margins
Unprecedented and sudden price surges in solvents and crude oil-linked raw materials caused gross margins to contract to 52.5% in Q1 FY27 from 54.0% in Q1 FY26.
Due to the sudden timing and severity of input cost inflation, the cost increases could not be fully passed on to customers during Q1, though full pass-through is planned for Q2.
EBITDA margins for the quarter also reflected a higher employee cost base driven by additional hiring undertaken for new growth initiatives.
05 · Demand, customers & order book
Where demand is coming from
Wanbury's API client base includes leading global generic players across over 50 countries, supported by ongoing regulatory submissions and DMF filings.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company continues to operate within a single primary business segment, namely 'Pharmaceuticals', encompassing both API manufacturing and branded formulations.
Geography and market mix
Geographic dispatches, particularly API exports to regulated international markets, faced temporary shipping delays owing to the ongoing crisis in the West Asia region.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The new state-of-the-art manufacturing block at the Tanuku site in Andhra Pradesh remains under validation and commercialization, with commercial scale-up anticipated to contribute in upcoming quarters.
Projects, capex and execution
Part of the Rs. 205 crore aggregate borrowings availed during the quarter from non-banking financial companies was earmarked towards ongoing capital expenditure requirements.
08 · Strategy & new businesses
How the company is trying to change its growth mix
During the quarter, the board approved the allotment of 27,530 equity shares of face value Rs. 10 each to eligible employees exercising vested options under the Wanbury ESOP 2016 plan.
09 · Reported developments
What changed operationally
The API manufacturing facility at Tanuku successfully cleared a quality inspection by the Therapeutic Goods Administration (TGA) of Australia, enabling shipments of 3 additional APIs upon receipt of the GMP certificate.
The Patalganga facility successfully completed an inspection by the Ministry of Food and Drug Safety (MFDS), Korea, with zero observations between April 7 and April 9, 2026.
Consequent to debt refinancing and repayment of high-cost loans, 85,20,330 promoter-pledged equity shares (representing 40.65% of paid-up capital) were released on July 7, 2026.
10 · Pressure points & risks
What is not going smoothly
An unexpected spike in solvents and crude-oil-linked raw material costs compressed gross profit margins by 150 basis points year-on-year to 52.5% during Q1 FY27.
Geopolitical tensions and logistics disruptions in West Asia constrained revenue growth to 1.5% YoY by deferring API export dispatches.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
The company restructured its debt profile by substituting high-cost obligations with Rs. 205 crore from NBFCs, setting up reduced finance costs from Q2 FY27.
Capital allocation & funding
Borrowings of Rs. 205 crore were availed from Axis Finance Limited and Poonawalla Fincorp to repay high-cost debt and fund capital expenditure, lowering borrowing costs from 12.5% to sub-10% effective July 1, 2026.
12 · Management guidance & targets
What management is targeting from here
Management anticipates a noticeable reduction in finance costs starting Q2 FY27 following the successful refinancing of borrowings at a lower interest rate.
13 · Beyond the numbers
What changed beyond the numbers
Reported update
Board Re-appointment
The board approved the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a term of five years effective August 21, 2026, subject to shareholder approval.
14 · Previous-quarter changes
What changed since the previous quarter
Gross margins moved from 60.4% in Q4 FY26 to 52.5% in Q1 FY27 due to sudden raw material price inflation that could not be immediately passed on.
15 · Key Q&A
The quarter, answered directly
What does Wanbury do?
Wanbury Limited is an established pharmaceutical company operating across active pharmaceutical ingredients (APIs) and domestic branded formulations, backed by over 37 years of operating history.
What is the clearest takeaway from Q1 FY27?
Wanbury Limited reported standalone revenue from operations of Rs. 165.58 crore for the quarter ended June 30, 2026, marking a modest 1.5% year-on-year growth compared to Rs. 163.18 crore in Q1 FY26.
What drove revenue or demand?
Revenue growth of 1.5% YoY to Rs. 165.58 crore was held back by logistics disruptions in West Asia that delayed several export dispatches during the quarter.
What mattered most for margins or profitability?
Unprecedented and sudden price surges in solvents and crude oil-linked raw materials caused gross margins to contract to 52.5% in Q1 FY27 from 54.0% in Q1 FY26.
What changed operationally beyond the headline numbers?
The new state-of-the-art manufacturing block at the Tanuku site in Andhra Pradesh remains under validation and commercialization, with commercial scale-up anticipated to contribute in upcoming quarters.
What is management guiding or targeting from here?
Management anticipates a noticeable reduction in finance costs starting Q2 FY27 following the successful refinancing of borrowings at a lower interest rate.
16 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
17 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Margin Recovery in Q2 FY27: Monitor whether gross margins and EBITDA margins rebound toward historical levels following the full pass-through of input cost inflation in Q2 FY27.
- 02
Finance Cost Savings: Track the realization of lower finance costs and reduced interest expense starting from Q2 FY27 under the sub-10% borrowing arrangement.
- 03
Commercialization of Tanuku Block: Observe the operational contribution and commercial scale-up of new APIs from the validated manufacturing block at the Tanuku site.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.